BEND, Ore. -- (BUSINESS WIRE) -- Bend Research Inc. announced its participation in presentations at upcoming industry gatherings that will focus on its newly developed full-spectrum process analytical technology (PAT) solutions for improved bioreactor operations.
By improving cell level “observability” and data-driven process “guidance,” it is possible to integrate data from both on-line and off-line tools to better understand and improve bioreactor yields while achieving target product quality.
In implementing PAT, biopharmaceutical companies are continually striving to gain a more fundamental understanding of what is happening to the cells within their environment, and the impact that the process has on the cell’s ability to deliver the target product quality. While implementation of on-line tools like dielectric spectroscopy and Raman are helping to provide insight, there is still a gap integrating the data produced by these techniques with off-line measurements. Key off-line measurements typically include cell density, viability, metabolite levels, titer and product quality metrics.
Bend Research Inc., in collaboration with other biopharmaceutical companies, is working to advance the novel Modular Automated Sampling Technology (MAST) platform. This platform provides samples directly from bioreactors to analytical devices while maintaining process sterility. For example, as a result of this integration, dielectric spectroscopy measurements can be corrected to more accurately estimate total and viable cell density.
From this new level of insight into the operation of the system, scientists can obtain enhanced data-driven “guidance” for key activities like cell line selection and optimized process operation. With this new technology, the bioprocess industry can make major advances toward advanced real-time testing, predictive control, and overall enhanced bioprocess design and operation.
“At Bend Research we are delivering innovative and transformative technologies for achieving target product quality through science and engineering,” said Dr. Lisa Graham, senior vice president of Bend Research. “We are eager to meet with clients and peers to discuss the latest developments in topics ranging from cell line management methodology to optimization of the production environment during each stage of the bioprocess development lifecycle to enhance production, reduce costs and shorten delivery time to market.”
Bend Research scientists will discuss their PAT solutions for improved bioreactors at the following international meetings and webinar:
Fifth Annual Bioprocessing Summit, August 19-23, Boston, Mass.: Lisa Graham, Ph.D., will present a poster titled, “PAT – Leveraging the Modular, Automated, Sampling Technology (MAST™) Platform for Merging In-line and At-line Analytical Technologies to Gain Optimized Cell-Level ‘Observability.’”
Jonathan Cape, Ph.D., will present a poster titled, “Shedding of Particulate Matter from Size-Exclusion Chromatography Resins: Origins of the Phenomenon and Mitigation Strategies for TSK GMPwxl.”
BioProcess International 2013, September 17-19 in Boston, Mass.: Clint Pepper, Ph.D., will present a poster titled, “Leveraging the Modular, Automated Sampling Technology (MAST™) Platform for Merging In-Line and At-Line Analytical Technologies to Gain Optimized Cell-Level ‘Observability’ and Data-Driven Process ‘Guidance.’”
Bend Research Webinar, September 26 at 8:00 a.m. PDT/11:00 a.m. EDT: Lisa Graham and Clint Pepper will present, “Driving Optimal Cell-Level ‘Observability’ and Data-Driven Process ‘Guidance’: Integrating the Modular, Automated Sampling Technology (MAST™) platform to enable a full-spectrum PAT solution.”
About Bend Research Inc.
For more than 35 years, Bend Research Inc. has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.
Bend Research Inc. provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies. With more than 250 employees, Bend Research Inc. is based in six state-of-the-art facilities in Bend, Oregon, USA.